melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The HLA-A0201 presented melanoma-associated MART-1/Melan-A derived peptide AAGIGILTV was employed to assess the impact of such position-97 mutations on HLA-A2 in peptide binding measured in an HLA-A2 reconstitution assay and presentation to AAGIGILTV-specific polyclonal or clonal T lymphocytes as measured by cytotoxicity, or interferon (IFN)-gamma and granulocyte/ macrophage colony-stimulating factor (GM-CSF) secretion.
|
8921947 |
1996 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The fine specificity of the TIL line PM2-B2 restricted by HLA-A1 was further characterized by evaluating specific granulocyte-macrophage colony-stimulating factor release in response to MHC class I-eluted peptides derived from HLA-A1(+) melanoma cell lines.
|
9816095 |
1996 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we constructed a targeted oncolytic vaccinia virus of Tian Tan strain Guang9 (VG9) expressing murine GM-CSF (VG9-GMCSF) and evaluated the antitumor effect of this recombinant vaccinia virus in a murine melanoma model.
|
26803055 |
2016 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adjuvant use of sequential GM-CSF and IL-2 +/- autologous vaccine was well tolerated with good patient compliance and seemed to benefit high-risk patients with surgically resected melanoma.
|
18593361 |
2008 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In an aggressive B16-F10 murine melanoma model, we evaluated the effectiveness and antitumor mechanisms triggered by a surgery adjuvant treatment that combined a local suicide gene therapy (SG) with a subcutaneous genetic vaccine (Vx) composed of B16-F10 cell extracts and lipoplexes carrying the genes of human interleukin-2 and murine granulocyte and macrophage colony stimulating factor.
|
24973616 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have transfected human melanoma cell line 518A2 with the cDNA encoding interleukin-2 (IL-2) or granulocyte-macrophage colony-stimulating factor (GM-CSF), and compared cytokine-producing clones for their ability to induce melanoma-specific cytotoxic T lymphocytes (CTL) from autologous peripheral blood mononuclear cells (PBMC) in vitro.
|
9336741 |
1997 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the potency of oncolytic adenovirus Ad5/3-D24-GMCSF on a panel of melanoma cell lines and animal models, and summarized the melanoma-specific human data from the Advanced Therapy Access Program (ATAP).
|
25821063 |
2015 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
|
10505851 |
1999 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants.
|
30450100 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus, type 1 (HSV-1) encoding granulocyte-macrophage colony stimulating factor (GM-CSF) and is approved for the treatment of melanoma and has shown therapeutic activity in murine tumors known to express high levels of STING.
|
31143509 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
|
31620131 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for gliomas and melanomas and discuss technical hurdles encountered.
|
16718522 |
2006 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.
|
12396624 |
2002 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine the tumor specificity, cytotoxicity and the antitumor activity of two conditionally replicating oncolytic adenoviruses, SKL001 and SKL002, which expressed granulocyte macrophage colony-stimulating factor (GM-CSF) or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA4) antibody, respectively, and determine their antitumor efficacy in A549 lung tumor model, B16F10 mouse melanoma tumor model and CMT-64 mouse small lung carcinoma tumor model.
|
25034886 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
|
28536308 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the development of binding and neutralizing antibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients receiving prolonged therapy with GM-CSF as adjuvant therapy of melanoma and the impact of these antibodies on biological effects.
|
25286079 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An oncolytic herpes simplex virus engineered to replicate selectively in tumor cells and to express granulocyte-macrophage colony-stimulating factor (GMCSF) was tested as a direct intralesional vaccination in melanoma patients.
|
19915919 |
2010 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GM-CSF-surface-modified B16.F10 melanoma cell vaccine.
|
16713660 |
2006 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GM-CSF, IL-12, and B7-2 genes can be transferred to human glioma and melanoma cell cultures efficiently by use of our retroviral vectors.
|
11950413 |
2002 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The unique timeline of rh-GM-CSF injections in a melanoma trial, during which yearly MRI scans showed subtle stable demyelination followed by RRMS onset shortly after discontinuation of treatment, may provide some insight on the role of GM-CSF in MS.
|
29414294 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We therefore determined the steady-state mRNA expression of five tyrosine kinase receptors, epidermal growth factor receptor (EGF-R), c-met, nerve growth factor receptor (NGF-R), colony-stimulating factor receptor (CSF-R) and c-kit, in eleven human melanoma cell lines with different metastatic potentials in nude mice.
|
7847808 |
1995 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF.
|
10930096 |
2000 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
|
31171039 |
2019 |
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
|
11061616 |
2000 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to determine the safety and antitumor activity of an autologous GM-CSF-secreting melanoma cell vaccine that was engineered ex vivo with recombinant replication-incompetent adenovirus harboring a human GM-CSF gene (Adv/hGM-CSF).
|
11676397 |
2001 |